Table 1. Smoking prevalence among chronic obstructive pulmonary disease patients in large randomised, placebo-controlled trials with inhaled corticosteroids and/or long-acting β2-agonists and/or long-acting anti-muscarinic drugs
First author [ref.]StudySubjects nAge yrsFEV1Smokers %
Vestbo [1]VESTBO290592.4 (86)77
Watson [2]EUROSCOP647532.5 (80)54
Vestbo [3]TRISTAN1465631.4 (45)51
Calverley [4]TORCH5343651.2 (45)45
Burge [5]ISOLDE751641.4 (50)38
Wedzicha [6]INSPIRE1323651.3 (39)38
  • Data for forced expiratory volume in 1 s (FEV1) is presented as L (% predicted).